We are live on ! Find out more
KNSA icon

Kiniksa Pharmaceuticals
KNSA

104 hedge funds and large institutions have $383M invested in Kiniksa Pharmaceuticals in 2022 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 38 increasing their positions, 27 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

161% more call options, than puts

Call options by funds: $4.68M | Put options by funds: $1.79M

144% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 9

41% more repeat investments, than reductions

Existing positions increased: 38 | Existing positions reduced: 27

32% more capital invested

Capital invested by funds: $290M → $383M (+$92.7M)

13% more funds holding

Funds holding: 92 → 104 (+12)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0.5% less ownership

Funds ownership: 87.3% → 86.8% (-0.5%)

Holders
104
Holders Change
+12
Holders Change %
+13.04%
% of All Funds
1.79%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
22
Increased
38
Reduced
27
Closed
9
Calls
$4.68M
Puts
$1.79M
Net Calls
+$2.89M
Net Calls Change
+$1.12M

Top Buyers

1
RCMNY
Rubric Capital Management (New York)
New York
+$10.5M
2
Millennium Management
Millennium Management
New York
+$7.77M
3
Ameriprise
Ameriprise
Minnesota
+$4.26M
4
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
+$3.62M
5
Goldman Sachs
Goldman Sachs
New York
+$3.09M

Top Sellers

1
GPP
Great Point Partners
Connecticut
-$11.7M
2
OM
Opaleye Management
Massachusetts
-$7.89M
3
PAMS
Pictet Asset Management (Switzerland)
Switzerland
-$5.63M
4
WP
Woodline Partners
California
-$3.23M
5
ACH
ArrowMark Colorado Holdings
Colorado
-$2.54M
Name Holding Trade Value Shares
Change 		Change in
Stake
BlackRock
1
BlackRock
New York
$46.6M +$1.06M +93,103 +3%
Vanguard Group
2
Vanguard Group
Pennsylvania
$39.5M +$1.72M +151,211 +5%
PAMS
3
Pictet Asset Management (Switzerland)
Switzerland
$39M -$5.63M -493,941 -14%
HA
4
HHLR Advisors
Cayman Islands
$37.5M – – –
BBA
5
Baker Bros. Advisors
New York
$35.9M – – –
RCMNY
6
Rubric Capital Management (New York)
New York
$18.6M +$10.5M +922,579 +176%
Hudson Bay Capital Management
7
Hudson Bay Capital Management
Connecticut
$15.4M -$1.99M -175,000 -13%
Millennium Management
8
Millennium Management
New York
$12.1M +$7.77M +681,827 +261%
ACH
9
ArrowMark Colorado Holdings
Colorado
$11.9M -$2.54M -223,043 -19%
Goldman Sachs
10
Goldman Sachs
New York
$11.6M +$3.09M +271,364 +43%
RHJA
11
Rice Hall James & Associates
California
$9.63M -$738K -64,740 -8%
State Street
12
State Street
Massachusetts
$7.85M +$302K +26,511 +5%
TCM
13
Tang Capital Management
California
$7.7M – – –
GIM
14
Granahan Investment Management
Massachusetts
$7.09M +$1.51M +132,355 +32%
Geode Capital Management
15
Geode Capital Management
Massachusetts
$6.72M -$91.1K -7,996 -2%
Morgan Stanley
16
Morgan Stanley
New York
$6.36M +$527K +46,290 +10%
LPC
17
Lion Point Capital
New York
$5.14M – – –
Dimensional Fund Advisors
18
Dimensional Fund Advisors
Texas
$5.05M -$156K -13,681 -3%
Ameriprise
19
Ameriprise
Minnesota
$4.8M +$4.26M +373,990 New
Jacobs Levy Equity Management
20
Jacobs Levy Equity Management
New Jersey
$4.08M +$3.62M +317,446 New
Northern Trust
21
Northern Trust
Illinois
$3.49M -$44.1K -3,871 -1%
Wellington Management Group
22
Wellington Management Group
Massachusetts
$3.44M -$110K -9,618 -3%
Fidelity Investments
23
Fidelity Investments
Massachusetts
$3.16M +$1.34K +118 +0%
Walleye Capital
24
Walleye Capital
New York
$2.87M -$828K -72,688 -25%
Charles Schwab
25
Charles Schwab
California
$2.63M +$1.38M +120,997 +145%
1
2 3 4 5

KNSA Hedge Fund Activity: Q3 2022 in Review

104 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Kiniksa Pharmaceuticals (KNSA) for Q3 2022, worth a combined $383M — up 32% from $290M a quarter earlier.

Buyers outnumbered sellers: 22 funds opened new KNSA positions and 9 closed out — a net gain of 13 holders — while 38 added to existing stakes and 27 trimmed.

The largest buyer was Rubric Capital Management (New York), adding an estimated $10.5M. The largest seller was Great Point Partners, exiting entirely with an estimated $11.7M sold.

  • 104 institutional investors held Kiniksa Pharmaceuticals (KNSA) as of Q3 2022, up from 92 in Q2 2022.
  • Funds reported $383M of Kiniksa Pharmaceuticals stock for Q3 2022, up 32% quarter-over-quarter.
  • 22 funds opened new Kiniksa Pharmaceuticals positions in Q3 2022 and 9 closed out, a net change of +13 holders.
  • The largest Kiniksa Pharmaceuticals buyer in Q3 2022 was Rubric Capital Management (New York), an estimated $10.5M added.
  • The largest Kiniksa Pharmaceuticals seller in Q3 2022 was Great Point Partners, an estimated $11.7M sold.

Based on aggregated 13F filings for Q3 2022.